WOODLAND HILLS, Calif.--(BUSINESS WIRE)--Dec. 20, 2005--Advanced Biotherapy, Inc. (OTCBB:ADVB) announced today that Dr. Daniel Levitt, Chief Medical Officer and Head of Clinical and Regulatory Affairs of Dynavax Technologies (Nasdaq:DVAX), has joined the Company’s scientific advisory board. Dr. Levitt has over 20 years of clinical, regulatory and management experience in the development of pharmaceuticals. He previously served as President of Research and Development at Protein Design Labs, Inc. (Nasdaq:PDLI), Chief Operating Officer and Head of Research and Development at Affymax, Inc., and a number of executive positions at Geron Corporation (Nasdaq:GERN), Sandoz Pharma Ltd., Sandoz Pharmaceuticals Corporation and Hoffmann-LaRoche, Inc.
